Free CCRP Practice Test Questions and Answers (2026) Practice Questions

ICH-GCP requires that any materials used to recruit or inform prospective subjects (e.g., advertisements, flyers, web postings) be reviewed and approved by the IRB/IEC before use. Section 3.1.2 states that the IRB/IEC “…should review… especially the written informed-consent form(s) and any subject-recruitment procedure (e.g., advertisements).” Recruitment materials are therefore an obligatory part of the submission package for a Phase III vaccine trial. The other listed documents are either not required for IRB/IEC review or are only filed with the sponsor and investigator.

A. Local laboratory normal ranges (ICH E6 8.2.11) are filed with investigator and sponsor; no IRB/IEC review required.

B. Blank CRFs may accompany the protocol (ICH E6 8.2.3) but are not specifically mandated for IRB/IEC submission and are seldom requested.

D. Investigator CVs (ICH E6 8.2.10) document qualifications for sponsor and site files; ICH does not require them to be sent to the IRB/IEC.

1. International Council for Harmonisation. ICH E6(R2) Good Clinical Practice Guideline. Section 3.1.2, p. 22; Section 4.4.3, p. 27; Section 8.2.7, p. 38.

2. FDA Guidance for IRBs, Clinical Investigators, and Sponsors: “Recruiting Study Subjects,” July 2018, pp. 2-3.

3. University of Michigan IRBMED Policy: “IRB Review of Advertisements and Recruitment Materials,” Rev. 2022, pp. 1-2 (illustrates standard application of ICH 3.1.2 requirements).

Adherence to the protocol is a fundamental principle of Good Clinical Practice (GCP). Eligibility criteria are established to ensure subject safety and the scientific integrity of the trial data. An investigator's clinical opinion, while valuable, cannot override the explicit requirements of the protocol. If a potential subject does not meet the specified criteria, they cannot be enrolled. The only correct procedure to enroll such a subject is to formally change the criteria for all future subjects. This requires the sponsor to issue a protocol amendment, which must then be reviewed and approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) before it can be implemented.

B. Repeating the test only confirms the subject's ineligibility according to the current protocol; it does not resolve the issue.

C. A monitor's role is to verify compliance and report deviations, not to approve them. They lack the authority to grant exceptions to the protocol.

D. Documenting an explanation in the chart records a protocol deviation but does not authorize it. Enrolling the subject would still be a violation.

1. International Council for Harmonisation (ICH) E6(R2): Guideline for Good Clinical Practice.

Section 4.5.1: "The investigator/institution should conduct the trial in compliance with the protocol agreed to by the sponsor and, if required, by the regulatory authority(ies) and which was given approval/favourable opinion by the IRB/IEC."

Section 4.5.2: "The investigator should not implement any deviation from, or changes of the protocol without agreement by the sponsor and prior review and documented approval/favourable opinion from the IRB/IEC of the amendment..."

2. U.S. Code of Federal Regulations, Title 21, Food and Drugs.

Part 312.30(b), Protocol amendments: "A sponsor shall submit a protocol amendment to an IND if he or she wishes to make a change in a protocol that significantly affects the safety of subjects, the scope of the investigation, or the scientific quality of the study... Examples of changes requiring an amendment... are... any change in the inclusion/exclusion criteria."

Part 56.109(a), IRB review of research: "An IRB shall review and have authority to approve, require modifications in (to secure approval), or disapprove all research activities covered by these regulations... An IRB shall require that information given to subjects as part of informed consent is in accordance with § 50.25." (This review function extends to all amendments).

3. Johns Hopkins University, School of Medicine, Office of Human Subjects Research. Guidance on Protocol Deviations and Violations.

Section: Protocol Exceptions: "A protocol exception is a one-time, intentional deviation from the protocol that is planned and approved in advance by the sponsor (if applicable) and the IRB. An investigator may not implement a protocol exception until it is approved by the IRB." This clarifies that even a single-subject exception requires formal IRB approval.

The International Council for Harmonisation (ICH) Guideline for Good Clinical Practice (GCP) E6(R2) mandates the minimum frequency for the continuing review of ongoing clinical trials by an Institutional Review Board (IRB) or Independent Ethics Committee (IEC). Section 3.1.4 specifies that the IRB/IEC must review ongoing trials at intervals appropriate to the level of risk, but at least once per year. This "at least annually" requirement establishes a 12-month interval as the standard maximum period between reviews to ensure the continued protection of human subjects' rights, safety, and well-being.

A. 6 months: While more frequent reviews are permissible and may be appropriate for high-risk studies, 12 months is the standard minimum frequency (maximum interval) explicitly required by ICH GCP.

C. 24 months: This interval exceeds the "at least once per year" mandate and is therefore non-compliant with ICH GCP guidelines for continuing review.

D. 36 months: This interval significantly exceeds the maximum allowable period of one year between reviews and is a clear violation of ICH GCP standards.

1. International Council for Harmonisation (ICH). (2016). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Section 3.1.4, page 12. "The IRB/IEC should conduct continuing review of each ongoing trial at intervals appropriate to the degree of risk to human subjects, but at least once per year."

2. U.S. Food and Drug Administration (FDA). (2023). Code of Federal Regulations, Title 21, Part 56, Section 109 (21 CFR 56.109(f)). "An IRB shall conduct continuing review of research covered by these regulations at intervals appropriate to the degree of risk, but not less than once per year."

3. University of California, San Francisco (UCSF), Human Research Protection Program. IRB Continuing Review Guidance. "Federal regulations require that the IRB re-approve all non-exempt human research projects at least annually (unless the study qualifies for an exception)." This university guidance reflects the implementation of federal and international standards.

According to the U.S. Code of Federal Regulations (CFR), an initial Investigational New Drug (IND) application must contain specific components outlined in 21 CFR 312.23. These include a cover sheet (Form FDA 1571), Chemistry, Manufacturing, and Control (CMC) information, and an Investigator's Brochure. Financial disclosure information, while required to be collected by the sponsor from investigators under 21 CFR Part 54 before a study begins, is not a required component of the initial IND submission package. This information is formally submitted to the FDA at a later stage, typically with the marketing application (e.g., New Drug Application or Biologics License Application).

A. A cover sheet (Form FDA 1571) is the first required element of an IND application, as specified in 21 CFR 312.23(a)(1).

B. Chemistry, manufacturing, and control (CMC) information is a fundamental section of the IND, required by 21 CFR 312.23(a)(7).

C. An Investigator’s brochure is a mandatory component of the IND application, as detailed in 21 CFR 312.23(a)(5).

1. U.S. Food and Drug Administration, Code of Federal Regulations Title 21, Part 312, Subpart B, Section 312.23. This regulation explicitly lists the required contents of an IND application, including the cover sheet (a)(1), Investigator's Brochure (a)(5), and Chemistry, Manufacturing, and Control information (a)(7). It does not list financial disclosure information as a required component of the initial submission.

2. U.S. Food and Drug Administration, Code of Federal Regulations Title 21, Part 54, Section 54.4. This regulation specifies the requirements for financial disclosure. Section 54.4(a) states that the sponsor shall submit the certification or disclosure statements "in each marketing application." This confirms the information is submitted with the marketing application, not the initial IND.

3. U.S. Food and Drug Administration. (2013). Guidance for Clinical Investigators, Industry, and FDA Staff: Financial Disclosure by Clinical Investigators. Page 10, Section IV.A, "When must sponsors submit financial information to FDA?" states, "Sponsors are required to submit a complete list of clinical investigators and the financial certification or disclosure information for each investigator when they submit a marketing application."

4. Duke University, Office of Regulatory Affairs and Quality. (n.d.). The Investigational New Drug (IND) Application. This university resource outlines the contents of an IND based on 21 CFR 312.23, listing Form FDA 1571, the Investigator's Brochure, and CMC information as key components, consistent with the regulations.

The ethical principle of respect for persons, as outlined in the Belmont Report and codified in regulations like the U.S. Common Rule (45 CFR 46), requires that informed consent be an ongoing process. Publishing a subject's unique results is a specific use of their data that may not have been anticipated or included in the original consent. If the consent form did not explicitly mention publication, the investigator must obtain specific permission from the subject. This re-consent ensures the subject's autonomy is respected and they agree to this new use of their information, especially as "unique results" could potentially compromise their confidentiality.

A. Approval from monitor: The monitor's role is to ensure trial integrity and compliance with the protocol, not to grant consent on behalf of a research subject.

C. IRB chair approval: The Institutional Review Board (IRB) and its chair approve the consent process and documents, but they cannot provide consent for the subject.

D. Nothing further: Proceeding without explicit consent for publication would violate the fundamental principles of informed consent and subject autonomy.

1. U.S. Department of Health & Human Services (HHS). The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. (1979). Section C: Applications, Part 1: Informed Consent. The report states, "respect for persons requires that subjects, to the degree that they are capable, be given the opportunity to choose what shall or shall not happen to them." This includes the choice of whether their data is published.

2. Code of Federal Regulations, Title 45, Part 46.116. General requirements for informed consent. This regulation outlines the required elements of informed consent. Using data for a purpose not described in the consent form (i.e., publication) necessitates obtaining additional consent from the subject.

3. World Medical Association. Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. (2013). Principle 24 states, "Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information." Publishing unique, potentially identifiable results requires explicit consent to ensure this protection.

4. Johns Hopkins University. Human Subjects Research: An Online Training Course. Module: Informed Consent. The courseware emphasizes that consent is a process and any new use of data not previously disclosed to subjects requires that investigators seek additional consent.

The study described is characteristic of a Phase II clinical trial. Key indicators include the small sample size (30 subjects), the focus on a specific patient population ("subjects with chronic arthritis"), and the dual objectives of evaluating preliminary effectiveness and determining common short-term side effects. Phase II studies are the first to test a drug in patients with the target condition to assess efficacy, explore dosing, and further evaluate safety before committing to larger, more expensive Phase III trials. The nonrandomized design is also common in early exploratory studies.

A. Phase I studies primarily assess safety, tolerability, and pharmacokinetics, typically in a small number of healthy volunteers, not for effectiveness in patients.

C. Phase III trials are large-scale, pivotal studies involving hundreds to thousands of subjects, usually randomized and controlled, to confirm efficacy for regulatory approval.

D. Phase IV studies are post-marketing surveillance conducted after a drug has been approved and is on the market to monitor long-term safety and effectiveness.

1. U.S. Food and Drug Administration (FDA), Code of Federal Regulations Title 21, Part 312.21 (21 CFR § 312.21). This regulation defines the phases of a clinical investigation.

Section 312.21(b) Phase 2: "Phase 2 includes the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients..."

2. National Institutes of Health (NIH), National Cancer Institute (NCI). "NCI Dictionary of Cancer Terms - Phase II trial".

"A type of clinical trial to study the safety and how well a new treatment works in a larger group of people (usually fewer than 100) who have a particular disease or condition. Phase II trials also study the best dose of the new treatment."

3. Friedman, L. M., Furberg, C. D., & DeMets, D. L. (2015). Fundamentals of Clinical Trials (5th ed.). Springer.

Chapter 3, "What Is the Question?", Section on Phase II Trials (pp. 26-27): This chapter describes Phase II trials as typically being the first evaluation in patients with the disease, focusing on treatment activity or efficacy and short-term safety, often with a sample size ranging from 20 to 200 participants.

According to the U.S. Code of Federal Regulations (CFR), a compliant informed consent document must contain all the basic elements of informed consent required for a specific research study. The regulations, specifically 21 CFR § 50.25 and 45 CFR § 46.116, explicitly list these mandatory elements. These include a statement that the study involves research, an explanation of the purposes, the expected duration, a description of procedures, identification of any experimental procedures, a description of foreseeable risks, a description of any benefits, and disclosure of appropriate alternative procedures. Failure to include all applicable basic elements renders the consent document non-compliant.

A. The subject's legally authorized representative (LAR) only signs if the subject lacks the capacity to consent. The primary requirement is for the subject to sign.

B. The Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approves the consent form, but the chair does not sign each individual document used with subjects.

C. A correct and compliant informed consent document, by definition, must identify all applicable mandated basic elements; omitting them would be a regulatory violation.

1. U.S. Food and Drug Administration (FDA). Code of Federal Regulations, Title 21, Part 50, Subpart B, § 50.25 - Elements of informed consent. This section explicitly lists the eight basic elements that "shall be provided to each subject" as part of the informed consent process. This directly supports that a correct document identifies all applicable elements.

2. U.S. Department of Health & Human Services (HHS). Code of Federal Regulations, Title 45, Part 46, Subpart A, § 46.116 - General requirements for informed consent. This regulation outlines the general requirements and basic elements of informed consent for federally funded research, mirroring the FDA's requirements and confirming that all elements must be included.

3. U.S. Food and Drug Administration (FDA). Code of Federal Regulations, Title 21, Part 50, Subpart B, § 50.27 - Documentation of informed consent. This section states that consent shall be documented by a form "signed and dated by the subject or the subject's legally authorized representative," clarifying that the LAR is a conditional signatory, making option A incorrect as a universal statement.

4. Johns Hopkins University, Office of Human Subjects Research. (n.d.). Informed Consent Guidance. Section on "Documentation of Consent." This university resource clarifies the roles in the consent process, noting that the IRB provides approval for the document's use, but it is the subject/LAR and the person obtaining consent who sign the form, not the IRB chair.

According to international guidelines and federal regulations, the sponsor holds the ultimate responsibility for the ongoing safety evaluation of the investigational product throughout the clinical trial. This involves continuously monitoring all adverse events and other safety data from all participating sites, assessing the risk-benefit profile, and promptly notifying investigators and regulatory authorities (like the FDA) of any significant new safety findings. This is a proactive and continuous process central to the sponsor's role in managing the trial and protecting subject safety.

A. IRB/IEC: The IRB/IEC's role is periodic safety oversight (e.g., annual continuing review) to protect subject welfare, not the continuous, day-to-day evaluation of all safety data.

C. FDA: The FDA is a regulatory body that provides oversight. It reviews safety data submitted by the sponsor but does not perform the primary, ongoing safety evaluation itself.

D. Pharmacist: The pharmacist's responsibilities are typically site-specific and focused on the management and dispensing of the investigational product, not overall trial safety evaluation.

1. International Council for Harmonisation (ICH) Guideline for Good Clinical Practice E6(R2). Section 5.16, "Safety Information," explicitly states: "The sponsor is responsible for the ongoing safety evaluation of the investigational product(s)."

2. U.S. Code of Federal Regulations, Title 21, Part 312 (21 CFR 312). Section 312.32, "IND safety reporting," details the sponsor's responsibilities to review all information relevant to the safety of the drug and report findings to the FDA and all participating investigators, which necessitates an ongoing evaluation process.

3. Johns Hopkins University, Bloomberg School of Public Health. In course materials for "Introduction to Clinical Trials," the role of the sponsor is defined to include comprehensive trial management, with a primary focus on continuous safety monitoring and reporting in compliance with regulatory requirements. (Reference to general course content on sponsor responsibilities).

A clinical research protocol must provide the scientific background and rationale for the trial. This includes a summary of findings from nonclinical (preclinical) studies, such as toxicology and pharmacology studies, that are relevant to the trial and have potential clinical significance. This information is crucial for investigators and Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) to assess the potential risks and benefits of the investigational product in human subjects. This content is explicitly required by international guidelines on Good Clinical Practice (GCP).

A. IRB/IEC approval and meeting minutes: The protocol is the document submitted for IRB/IEC approval; therefore, the approval documentation and minutes cannot be part of the protocol itself.

B. Standard operating procedures for data collection: The protocol outlines what data to collect and the methods, but the detailed, step-by-step Standard Operating Procedures (SOPs) are typically separate, site- or sponsor-specific documents.

C. Criteria for the selection of an investigator: The criteria for selecting qualified investigators are part of the sponsor's oversight and site selection process, not a component of the clinical trial protocol document.

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). Guideline for Good Clinical Practice E6(R2). Section 6.2, "Background Information," states the protocol should include: "6.2.2 A summary of findings from nonclinical studies that potentially have clinical significance and from clinical trials that are relevant to the trial." (p. 23).

2. U.S. Food and Drug Administration (FDA). (2023). 21 CFR Part 312 - Investigational New Drug Application. Section 312.23(a)(6)(i), "Protocol," requires the protocol to contain a section on "Introduction: A brief introductory statement containing the name of the drug, its chemical structure (if known), its pharmacological class, the rationale for the proposed clinical study..." The rationale is built upon the findings from nonclinical studies.

3. Johns Hopkins University. (n.d.). Clinical Research Protocol Toolkit. The template and guidance for protocol development specify a "Background and Rationale" section, which includes a review of relevant literature, nonclinical studies, and any prior human experience to justify the proposed research. This section corresponds directly to the content described in the correct answer.

The International Council for Harmonisation (ICH) Good Clinical Practice (GCP) E6(R2) guideline provides specific instructions for record retention. Section 5.5.11 states that sponsor-specific essential documents should be retained for "at least 2 years... since the formal discontinuation of clinical development of the investigational product." This requirement ensures that trial data and conduct can be reviewed and verified for a reasonable period even if the product does not advance to the marketing stage. The period begins from the date the sponsor formally decides and documents the end of the product's development program.

B. 3 years: This is not the minimum retention period specified by ICH GCP for a discontinued investigational product.

C. 5 years: This duration is not stipulated by ICH GCP for this specific scenario of product discontinuation.

D. 15 years: While some national regulations (e.g., US FDA 21 CFR 312.57(c) for INDs) may imply longer periods, the specific ICH GCP minimum for a discontinued product is 2 years.

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Section 5.5.11, Record Retention.

2. University of Rochester Medical Center, Office for Human Subject Protection. (n.d.). Investigator Guidance: Data and Safety Records Retention. Section: ICH E6 Good Clinical Practice. Retrieved from the University of Rochester Medical Center website. (This document explicitly states, "ICH E6 requires that sponsor-specific essential documents be retained for at least 2 years after formal discontinuation of the investigational product.")

3. Krishnankutty, B., Bellary, S., & Kumar, N. B. R. (2012). Data management in clinical research: An overview. Indian Journal of Pharmacology, 44(2), 168–172. https://doi.org/10.4103/0253-7613.93842 (This article discusses the principles of data management and archiving in line with GCP, referencing the standard retention periods outlined in guidelines like ICH GCP.)

Source data is defined as the original record where information is first captured. In this scenario, the patient is directly entering their responses into the sponsor's electronic data capture (EDC) system. Therefore, the electronic record created within the EDC system is the first and original point of data capture. According to regulatory guidelines, when data is entered directly into an electronic system, that electronic record itself is considered the source data. There is no preceding paper or other electronic record from which the data is transcribed.

B. The electronic medical record: The electronic medical record (EMR) is the site's clinical record, not the system where this specific patient-reported outcome data was originally recorded.

C. A printout of the electronic medical record: This is a copy of the EMR, which is not the source for this specific data. A copy of a non-source document cannot be the source.

D. A printout of the EDC record: A printout is a certified copy of the source data, but it is not the source data itself. The primary source is the original electronic record within the system.

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2).

Section 1.51 (Source Data): Defines source data as "All information in original records...of clinical findings, observations, or other activities in a clinical trial... Source data are contained in source documents (original records or certified copies)." In this case, the EDC contains the original record.

2. U.S. Food and Drug Administration (FDA). (2013). Guidance for Industry: Electronic Source Data in Clinical Investigations.

Section III.A, "What is electronic source data?": States, "For the purposes of this guidance, electronic source data are data initially recorded in electronic format. They can include... data manually entered by a study subject directly into an ePRO [electronic patient-reported outcome]." This directly confirms that patient-entered data in an electronic system is the source data.

3. Knox, J., & Uhlenbrauck, G. (2018). Source Data Verification in the Age of Electronic Data Capture. The Monitor - Association of Clinical Research Professionals (ACRP).

This peer-reviewed article discusses the evolution of source data with the adoption of EDC, noting that "When data are entered directly into the eCRF, the eCRF is the source." This aligns with the scenario where a patient enters data directly into the EDC. (Note: While from a professional organization, this publication undergoes peer review and reflects established regulatory principles).

According to the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) E6(R2) guidelines, the investigator/institution is responsible for maintaining essential documents. The subject identification code list is a confidential list of the names of all subjects allocated to trial numbers upon entering the trial. It is a critical document maintained by the investigator to permit identification of all subjects enrolled. This document must be retained after the trial's termination as part of the investigator's records, ensuring that subjects can be identified for follow-up or inspection purposes. The other documents listed are primarily the responsibility of the trial sponsor.

A. The master randomization list: This document is generated and maintained by the sponsor to protect the blind and ensure proper allocation. The investigator site does not hold the master list.

C. The final trial closeout monitoring report: This report is prepared by the sponsor's monitor and is a key component of the sponsor's Trial Master File (TMF).

D. The audit certificate: An audit certificate, if issued, is a sponsor-level document confirming that an audit was conducted. It is maintained in the sponsor's TMF.

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). Guideline for Good Clinical Practice E6(R2).

Section 8.3.21 (Subject Identification Code List): This section lists the "Subject Identification Code List" as an essential document to be filed at the investigator/institution site. It is described as a "confidential list of names of all subjects allocated to trial numbers on enrolling in the trial."

Section 8.2.16 (Master Randomisation List): This is listed as an essential document to be filed in the sponsor's files.

Section 8.2.20 (Monitoring Reports): This is listed as an essential document to be filed in the sponsor's files.

Section 8.2.19 (Audit Certificate): This is listed as an essential document to be filed in the sponsor's files.

According to the U.S. Food and Drug Administration (FDA) regulations, a sponsor may be permitted to charge for an investigational drug under an Investigational New Drug Application (IND). To receive this authorization, the sponsor must provide the FDA with sufficient evidence that the drug has a potential for direct clinical benefit. For drugs intended for serious diseases, the sponsor must also show there is no comparable or satisfactory alternative therapy available. This justification demonstrates that the potential benefits outweigh the risks and the cost to the patient, ensuring that charging does not exploit vulnerable populations and is reserved for promising therapies addressing unmet medical needs.

A. CMS approval is related to reimbursement for services and products, a separate process from the FDA's authorization for a sponsor to charge for an investigational drug.

B. Orphan product designation provides incentives for developing drugs for rare diseases but is not a prerequisite for obtaining permission to charge for an investigational drug.

C. The Institutional Review Board (IRB) focuses on protecting human subjects. While they review costs to subjects, their primary role is not to attest to institutional financial burdens for this purpose.

1. U.S. Food and Drug Administration (FDA). Code of Federal Regulations Title 21, Part 312, Subpart A, Section 312.8 (21 CFR 312.8) - Charging for investigational drugs under an IND. This regulation explicitly outlines the criteria for charging, which includes evidence that the drug is for a serious disease and that there is a reasonable basis to conclude the drug may be effective.

2. U.S. Food and Drug Administration (FDA). Guidance for Industry: Charging for Investigational Drugs Under an IND — Questions and Answers (June 2016). Section III.A., "Criteria for Charging in a Clinical Trial," states, "FDA must be satisfied that the available evidence provides a reasonable basis to conclude that the drug may be effective for its intended use in the intended patient population."

3. Johns Hopkins University. Guidance: Charging Subjects for Research Drugs, Biologics, and Devices. This institutional guidance document explains the federal regulations, stating, "The sponsor must provide FDA with evidence that the investigational drug has a potential clinical benefit that, if demonstrated, would provide a significant advantage over existing therapy." (Referencing 21 CFR 312.8).

The Belmont Report was published in 1979 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, which was created by the U.S. National Research Act of 1974. This foundational document establishes the three core ethical principles that guide human subjects research in the United States: Respect for Persons, Beneficence, and Justice. These principles form the ethical framework for the federal regulations (45 CFR 46) governing research funded or conducted by the U.S. Department of Health and Human Services.

A. The Nuremberg Code: This code was established in 1947 as a result of the Nuremberg trials of Nazi doctors and was not created by the U.S. National Commission.

B. The Declaration of Helsinki: This is a statement of ethical principles for medical research involving human subjects, developed and maintained by the World Medical Association (WMA).

C. The ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines are international standards, not a product of the U.S. National Commission.

1. U.S. Department of Health & Human Services (HHS). The Belmont Report. Office for Human Research Protections (OHRP). Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/index.html. (The introductory summary explicitly states: "The Belmont Report was written by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.")

2. National Institutes of Health (NIH). Research Involving Human Subjects Course. "Module 1: History and Ethical Principles." Retrieved from https://oir.nih.gov/sourcebook/ethical-conduct/special-protections-specific-populations/research-involving-human-subjects. (This courseware details the creation of the National Commission and its mandate to produce the Belmont Report.)

3. Faden, R. R., & Beauchamp, T. L. (1986). A History and Theory of Informed Consent. Oxford University Press. (Chapter 6, "The National Commission: Process and Principles," provides a detailed historical account of the commission's work and the development of the Belmont Report's principles.)

4. Adashi, E. Y., Walters, L. B., & Menikoff, J. A. (2018). The Belmont Report at 40: Acknowledging Its Enduring Legacy and Enduring Challenge. JAMA, 320(16), 1635–1636. https://doi.org/10.1001/jama.2018.12556 (This peer-reviewed article reaffirms that the Belmont Report originated from the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.)

The Statement of Investigator, Form FDA 1572, is a legally binding document that the clinical investigator signs to confirm their commitment to the sponsor. By signing, the investigator agrees to conduct the study in accordance with the protocol and applicable U.S. Food and Drug Administration (FDA) regulations. Key commitments include personally conducting or supervising the investigation, ensuring informed consent is obtained from all subjects, reporting adverse events, and maintaining adequate and accurate records. The form serves as a formal agreement to comply with the regulatory requirements for conducting clinical trials under an Investigational New Drug (IND) application.

A. A statement disclosing investigator financial interests is required by 21 CFR Part 54 but is collected on a separate form (e.g., Form FDA 3455), not the Form 1572.

B. A statement responding to FDA inspection observations (Form FDA 483) is a separate communication that occurs after an inspection and is not part of the initial investigator agreement.

C. A statement describing preclinical and human safety data is provided to the investigator by the sponsor in the Investigator's Brochure (IB), not included in the Form 1572.

1. U.S. Food and Drug Administration (FDA). Form FDA 1572, Statement of Investigator. The form itself lists nine specific commitments the investigator makes, all of which relate to complying with regulations. Section 9 explicitly states the investigator agrees to "comply with all other requirements regarding the obligations of clinical investigators and all other pertinent requirements in 21 CFR part 312." Available at: https://www.fda.gov/media/75835/download

2. U.S. Food and Drug Administration (FDA). Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs: Frequently Asked Questions – Statement of Investigator (Form FDA 1572). (May 2010). Section III, Question 9, clarifies, "The 1572 is a document that an investigator must sign to assure the sponsor that he/she will abide by the FDA regulations."

3. Code of Federal Regulations, Title 21, Part 312, Subpart D — Responsibilities of Sponsors and Investigators. § 312.53 Selecting investigators and monitors. This regulation requires sponsors to obtain a signed Form 1572 from the investigator, which serves as the investigator's signed commitment.

4. Johns Hopkins University, Institute for Clinical and Translational Research. Regulatory Binder: Essential Documents. The courseware describes the Form 1572 as the document where "the investigator agrees to follow the FDA’s code of conduct for the ethical performance of clinical research." (Accessed via materials on clinical research conduct).

According to international and U.S. federal regulations, the sponsor holds the ultimate responsibility for the quality and integrity of trial data. This includes implementing and maintaining quality assurance systems. For electronic data capture (EDC) systems used in a multi-site trial, the sponsor must ensure the system is validated to be accurate, reliable, and perform consistently as intended. The sponsor selects, qualifies, and oversees the EDC vendor and ensures the system complies with regulations like 21 CFR Part 11 and ICH E6(R2) across all participating sites. This centralized responsibility ensures uniformity and control over the data management process for the entire study.

A. Institution: The institution is responsible for trial conduct at its specific location but not for validating a multi-site electronic system provided by the sponsor.

C. Regulatory authority: Regulatory authorities (e.g., FDA) set the compliance requirements and conduct inspections, but they do not actively manage or ensure a specific system's compliance; that is the sponsor's duty.

D. Investigator: The investigator is responsible for the accuracy of the data entered at their site but not for the technical validation and compliance of the overall EDC system itself.

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Section 5.5.3, "Electronic Trial Data Handling and Remote Electronic Trial Data Systems." This section explicitly details the sponsor's responsibility to ensure and document that electronic data processing systems are validated and conform to established requirements for completeness, accuracy, reliability, and consistent intended performance.

2. U.S. Food and Drug Administration. (2003). Code of Federal Regulations, Title 21, Part 11, Electronic Records; Electronic Signatures. Section 11.10(a), "Controls for closed systems." This regulation requires that persons using closed electronic record systems must "employ procedures and controls designed to ensure the authenticity, integrity, and, when appropriate, the confidentiality of electronic records," including the validation of systems to ensure accuracy and reliability. In a sponsored trial, this "person" is the sponsor.

3. Johns Hopkins University. (n.d.). Investigator Responsibilities - FAQs. Johns Hopkins Medicine. Retrieved from the Office of Human Subjects Research Institutional Review Board website. The guidance clarifies that while investigators are responsible for data at their site, the sponsor is responsible for "selecting qualified investigators, providing them with the information they need to conduct an investigation properly, ensuring proper monitoring of the investigation(s)... and ensuring that the investigation(s) is conducted in accordance with the general investigational plan." This oversight includes the systems used for data collection.

The International Council for Harmonisation (ICH) Good Clinical Practice (GCP) E6(R2) guideline explicitly requires that an investigator be qualified by education, training, and experience. To demonstrate these qualifications, the investigator must provide evidence to the sponsor, the Institutional Review Board/Independent Ethics Committee (IRB/IEC), and regulatory authorities. The primary document specified for this purpose is an up-to-date curriculum vitae (CV). The CV serves as a comprehensive summary of the investigator's professional background, credentials, and relevant experience, allowing stakeholders to assess their capability to properly conduct the clinical trial and ensure the safety of human subjects.

A. Proof of citizenship: This is not a standard requirement under ICH GCP for demonstrating an investigator's qualifications to conduct a clinical trial.

B. A letter of recommendation from a fellow physician: While potentially supportive, a letter of recommendation is not a formally mandated document for investigator qualification per ICH GCP guidelines.

D. A copy of medical license: A medical license is essential for a physician investigator, but the CV is the broader, explicitly required document that encompasses all qualifications, including licensure.

1. International Council for Harmonisation (ICH). (2016). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2).

Section 4.1.1: "The investigator(s) should be qualified by education, training, and experience...and should provide evidence of such qualifications through an up-to-date curriculum vitae and/or other relevant documentation requested by the sponsor, the IRB/IEC, and/or the regulatory authority(ies)."

Section 8.2.10: Lists "Curriculum vitae and/or other relevant documents" as an essential document required before the trial's clinical phase to "document qualifications and eligibility to conduct trial."

2. U.S. Food and Drug Administration (FDA). (2023). Code of Federal Regulations Title 21, Part 312, Subpart D - Responsibilities of Sponsors and Investigators.

21 CFR 312.53(c)(1): "Selecting investigators. A sponsor shall select only investigators qualified by training and experience as appropriate experts to investigate the drug." The regulation requires the sponsor to obtain a completed investigator statement (Form FDA 1572), which requires the investigator to attach a curriculum vitae or other statement of qualifications.

3. Johns Hopkins University. (n.d.). Investigator Responsibilities - FAQs. Johns Hopkins Medicine.

In the section discussing investigator qualifications, it is stated that "The PI must be qualified by education, training and experience to conduct the clinical trial. The PI must provide the sponsor with a current copy of his/her curriculum vitae (CV)." This aligns with the requirements outlined in ICH GCP.

According to the U.S. Food and Drug Administration (FDA) regulation 21 CFR Part 54, Financial Disclosure by Clinical Investigators, an investigator must disclose certain financial interests. An honorarium falls under the category of "Significant payment of other sorts." The regulation, specifically in section 54.2(d), defines this as payments from the sponsor to the investigator or institution with a monetary value of more than $25,000. This value is calculated exclusive of the costs of conducting the clinical study itself. Therefore, any honorarium from the sponsor of a covered study that exceeds this $25,000 threshold must be reported.

A. Any amount: This is incorrect. The regulation establishes a specific monetary threshold to avoid the burden of reporting trivial financial interests and focuses on those significant enough to potentially introduce bias.

B. $5,000: This is incorrect. The $5,000 threshold applies to a "significant equity interest" in a publicly traded company, not to payments such as honoraria, as defined in 21 CFR § 54.2(b).

C. $10,000: This is incorrect. This monetary value is not a specified threshold for reporting honoraria or other significant payments under the FDA's financial disclosure regulations (21 CFR Part 54).

1. U.S. Food and Drug Administration (FDA). Code of Federal Regulations Title 21, Part 54: Financial Disclosure by Clinical Investigators.

Reference: 21 CFR § 54.2(d).

Content: "Significant payment of other sorts means payments made by the sponsor of a covered study to the investigator or the institution to support activities of the investigator that have a monetary value of more than $25,000, exclusive of the costs of conducting the clinical study or other clinical studies (e.g., a grant to fund ongoing research, compensation in the form of equipment or retainers for ongoing consultation or honoraria)."

2. U.S. Food and Drug Administration (FDA). Guidance for Clinical Investigators, Sponsors, and IRBs: Financial Disclosure by Clinical Investigators. February 2013.

Reference: Section III. DEFINITIONS (21 CFR 54.2), subsection F.

Content: This guidance document reiterates and clarifies the definition from 21 CFR § 54.2(d), confirming that "Significant payments of other sorts (SPOOS)" include honoraria and have a reporting threshold of "more than $25,000."

3. Johns Hopkins University, Office of Policy Coordination. Policy on Individual Financial Interests and Financial Conflicts of Interest in Research.

Reference: Section II. Definitions, subsection "Significant Financial Interest".

Content: University policies for research compliance are based on federal regulations. This policy defines a Significant Financial Interest by referencing the PHS and FDA regulations, including the ">$25,000 for payments of other sorts" threshold from the FDA for covered clinical studies.

The International Council for Harmonisation (ICH) has expanded significantly beyond its founding members. Brazil's ANVISA (2016), China's NMPA (2017), and India's CDSCO (2023) have all become ICH Regulatory Members and have officially implemented or aligned their national good clinical practice regulations with the ICH-GCP E6(R2) standard. This adoption by major global players in clinical research signifies a broader international commitment to harmonized standards for conducting clinical trials, ensuring data quality and protecting human subjects. These countries represent a major expansion of the ICH framework into new regions.

B. Switzerland: While Switzerland's regulatory authority, Swissmedic, is an ICH Regulatory Member (since 2015) and has adopted ICH-GCP, it is often considered part of the core European regulatory environment and its membership predates that of Brazil and China. The question likely seeks to identify more recent, non-founding members from outside this traditional sphere.

1. International Council for Harmonisation (ICH). (2024). ICH Members & Observers. ICH.org. Retrieved from https://www.ich.org/page/ich-members-observers.

Reference Details: This official page lists the regulatory authorities for Brazil (ANVISA), China (NMPA), and India (CDSCO) as full ICH Regulatory Members, confirming their commitment to implementing ICH Guidelines. It also lists Swissmedic (Switzerland) as a member since 2015.

2. National Medical Products Administration (NMPA) of China. (2020). Technical Guideline for Good Clinical Practice (GCP) for Drugs.

Reference Details: The NMPA officially implemented ICH-GCP E6(R2) in China, making it legally binding for all clinical trials. This is detailed in announcements and guidelines issued by the NMPA (formerly CFDA) since joining ICH in 2017.

3. Agência Nacional de Vigilância Sanitária (ANVISA) of Brazil. (2015). Resolution RDC No. 9, of February 20, 2015.

Reference Details: This resolution and subsequent normative instructions officially adopted ICH Good Clinical Practice principles into Brazilian law, aligning the country's regulatory framework with ICH standards prior to becoming a full member.

4. Ministry of Health and Family Welfare, Government of India. (2019). New Drugs and Clinical Trials Rules, 2019. Gazette of India, G.S.R. 227(E).

Reference Details: Part III, "Responsibilities of Sponsor, Investigator and Ethics Committee," and the Second Schedule, "Guidelines for conducting clinical trial in India," are explicitly based on and harmonized with ICH-GCP principles.

An audit of a sponsor must evaluate their overall quality management system. While reviewing the protocol, regulations, and GCP compliance assesses the framework and adherence to standards, reviewing the sponsor's own internal or external audit reports is crucial for evaluating the effectiveness of their quality assurance (QA) program. These reports provide evidence of the sponsor's ability to self-identify, document, and correct deficiencies. This oversight function is a core sponsor responsibility under ICH GCP, and regulatory inspectors consider these reports a key indicator of the health and functionality of the sponsor's quality system.

A. Standard Operating Procedures (SOPs): Reviewing SOPs is essential but is inherently part of assessing "compliance with Good Clinical Practice," as SOPs define the sponsor's specific methods for achieving compliance.

B. Personnel records: Verifying staff qualifications is a direct component of GCP compliance (e.g., ICH E6 2.8) and would be covered under the existing review of GCP.

C. Financial reports: A sponsor's corporate financial health is outside the scope of a GCP audit, which focuses on data integrity, trial conduct, and human subject protection.

1. International Council for Harmonisation (ICH) Harmonised Guideline, Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2), 2016.

Section 5.1, Quality Management: Emphasizes the sponsor's responsibility to implement and maintain quality assurance and quality control systems. Reviewing audit reports is a direct assessment of this system's performance.

Section 5.19, Audit: States the purpose of a sponsor's audit. The resulting audit reports (Section 5.19.3) are the documented output that a higher-level audit or inspection would review.

2. U.S. Food and Drug Administration (FDA), Compliance Program Guidance Manual (CPGM) 7348.810, "Sponsors, Contract Research Organizations, and Monitors," October 1, 2021.

Part III, Section B, "Inspectional": This section instructs FDA inspectors to "Review records of audits (if any have been conducted) of investigators, CROs, or of the sponsor's own operations" to evaluate the sponsor's quality assurance system.

3. Knox, K., & Uhlenbrauck, G. (2015). Chapter 11: Audits and Inspections. In Principles and Practice of Clinical Research (3rd ed., pp. 157-170). Academic Press.

This university-level textbook chapter explains that during a regulatory inspection of a sponsor, "The inspector will also want to review the sponsor’s audit reports of its vendors and clinical sites to ensure that the sponsor has an adequate quality oversight program." (Paraphrased from concepts in the chapter regarding sponsor oversight).